Researchers claim that an oral lipid nanoparticle medication inhibits the growth of tumors in mice, indicating that this is a viable treatment formulation for treating cancer linked to colitis.
According to research done at Georgia State University's Institute for Biomedical Sciences and results published in the journal Pharmaceutics, the oral medication formulation is made up of lipid nanoparticles called M13-loaded nanoliposomes (M13-NL).
The anti-ulcerative colitis drug M13 shows promise. IBD patients are more likely to develop colitis-associated malignancy, which is resistant to conventional chemotherapy regimens and includes ulcerative colitis and Crohn's disease.
Because pharmacological therapies are most successful in the early stages of cancer development, early detection and treatment of colitis-associated cancer can dramatically enhance patient survival. Depending on the exact prescription used, the adverse effects of current IBD pharmacological therapies can be severe and include immunosuppression, bone loss, liver toxicity, pancreatitis, and blood abnormalities.
There is a need for an accessible and safe therapy that may efficiently target and deliver medications to damaged tissue, lessen side effects, and alleviate symptoms. According to the research, current treatments must use efficient small-molecule drugs or colon-targeted delivery methods.
Previous research has shown that the M13-NL formulation can efficiently prevent chronic ulcerative colitis by targeting the colon and altering the gut microbiota in cultures outside the organism.
The capacity of the lipid nanoparticle formulation to absorb cancer cells was examined in this study, along with the possibility that the M13-NL formulation may shield animals from developing colitis-related cancer.
Senior author of the study, Didier Merlin, said, "Our findings demonstrate that oral administration of M13-NL prevents tumor development in mice, suggesting that M13-NL is a promising candidate for preventing colitis-associated cancer in patients with inflammatory bowel disease."
The mice employed in this work combine chronic inflammation and DNA damage, two critical variables implicated in the development of colitis-associated cancer. They have ongoing inflammation because their colons do not generate the anti-inflammatory cytokine IL-10. Azoxymethane (AOM) causes DNA damage in the colon, which results in the growth of colorectal cancers.
The study said that this made it possible for the researchers to evaluate the effectiveness of long-term oral administration of M13-NL against the emergence of colitis-associated malignancy.
Researchers concluded that more research is required to confirm these results and evaluate the safety and effectiveness of M13-NL in human clinical trials.